|Date||Title|| || |
|02/06/17||Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference|
|SOUTH SAN FRANCISCO, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13th at 5:30 PM Eastern Time at the Waldorf Astoria Hotel in New York.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of ... |
|01/23/17||Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs|
|FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017
Vosaroxin Day 180 List of Outstanding Issues Received; Company to go Before Scientific Advisory Group in April Prior to CHMP Opinion
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced clinical and regulatory updates to its two lead programs, SN... |